Companies › Mersana Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| upifitamab rilsodotin (XMT-1536) anti-NaPi2b antibody-drug conjugate | SLC34A2 | Phase 1 | Platinum Resistant Ovarian Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03319628 | upifitamab rilsodotin (XMT-1536) | Phase 1 | Platinum Resistant Ovarian Cancer | Oncology | May 2023 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.